Drug Database
LE

levonorgestrel (LCS12 / LCS G04209C / MLS)

✓ Approved

Takeda · PGR · Small Molecule

What is levonorgestrel?

levonorgestrel is a small molecule developed by Takeda. It is approved for therapeutic indications via surgical implantation.

Drug Profile

Brand NamesLCS12, LCS G04209C, MLS
CompanyTakeda
Drug ClassSmall Molecule
Molecular TargetPGR
RouteSurgical Implantation
StatusApproved

Mechanism of Action

Molecular Targets

levonorgestrel acts on 1 molecular target:

PGRprogesterone receptor (NR3C3, PR)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

levonorgestrel is developed for 2 unique indications across 1 therapeutic area.

Therapeutic AreaConditionPhase
Reproductive system and breast disordersMenstrual disorder✓ Approved
Reproductive system and breast disordersHeavy menstrual bleeding✓ Approved

Related Research Articles

PubMedHarefuah2026-10-18

[A delayed threat: S. aureus sepsis 4 years post-IUD insertion in a healthy young woman].

Dan Ofir O, Biham Oren O, Kedmi Aviya A, Azulay Hovav H et al.

Intrauterine devices (IUDs) are highly effective long-acting reversible contraceptives with an established safety profile. Infectious complications are rare and usually occur shortly after insertion, typically involving polymicrobial pathogens. Staphylococcus aureus is an uncommon pathogen in this context, but its biofilm-forming ability may contribute to delayed and severe presentations. A healthy 25-year-old primiparous woman developed septic shock four years after the insertion of a levonorgestrel-releasing intrauterine system (Mirena®). She was admitted to the intensive care unit with fever, abdominal pain, and hemodynamic instability requiring vasopressor support. The IUD was removed, and cultures grew methicillin-susceptible Staphylococcus aureus (MSSA), while blood cultures were negative. She subsequently improved following device removal, targeted intravenous antibiotics, and supportive intensive care. Notably, nasal carriage was negative in the patient but positive in her partner, suggesting a possible source of colonization. This case illustrates a rare but life-threatening complication of IUD use: septic shock secondary to S. aureus biofilm infection, manifesting years after device insertion. Clinicians should maintain a high index of suspicion for device-related infection in women with unexplained sepsis. Prompt device removal, targeted antimicrobial therapy, and multidisciplinary ICU care are critical for optimal outcomes. The possible contribution of partner colonization to the pathogenesis of such infections warrants further investigation.

PubMedHarefuah2026-10-18

[Intrauterine device placement during cesarean delivery: an immediate solution for postpartum contraception].

Ben David Chen C, Wolfovitz Amir A, Justman Naphtali N, Loberman Nimrod N et al.

Contraception availability is a global challenge. For many women, intrauterine device (IUD) placement during cesarean delivery offers an effective solution. This procedure is highly recommended for women seeking long-term reversible contraception, particularly low-compliance patients or those with limited access to postpartum healthcare services. It is also an ideal option for women with contraindications to estrogen therapy, patients with a history of multiple cesarean sections, or those who have undergone previous uterine surgeries, such as myomectomy, which are risk factors for uterine perforation during intra uterine device insertion. We describe a method for intrauterine device placement during cesarean delivery. Intrauterine devices in general, and this specific technique in particular, are endorsed by leading professional societies as a strategy for safe postpartum immediate contraception. The purpose of this paper is to raise awareness and increase the clinical availability of this safe, convenient, effective, and affordable solution, ultimately empowering patients with better family planning options.

PubMedFrontiers in reproductive health2026-10-17

Impact of contraceptive initiation on the cervicovaginal mucosa: results from the UMPALA multicentre, partially randomized patient-preference interventional trial.

Njoroge Betty B, Mugo Nelly N, Herrera Carolina C, Dominguez Karen K et al.

Long-acting contraceptives are widely used, providing superior efficacy and systemic safety; however, the impact of contraceptive initiation on female genital tract function and health has been understudied. Non-pregnant, HIV-uninfected women aged 18-50 years were enrolled in a dual-centre partially randomized patient-preference interventional trial (NCT04814927) and allowed to choose one of four contraceptive options, etonogestrel contraceptive implant, depot medroxyprogesterone acetate subcutaneous injection, levonorgestrel intrauterine device, and copper IUD, with a minimum target of 12 participants per arm and site. Sampling took place at baseline, 1 and 3 months after contraceptive initiation, and 1 month post-contraceptive discontinuation. Primary outcomes focused on mucosal function and health, while secondary and tertiary outcomes pertained to systemic and mucosal susceptibility to HIV-1 and HSV-2. Cervicovaginal samples from 112 enrolled participants showed transient, statistically significant changes in endpoints comparing baseline vs. 1 and 3 months after contraceptive initiation. Changes in pH, epithelial thickness, E-cadherin expression, antimicrobial peptides, glycogen, and lactic acid varied with contraceptive type and were typically transient. Serum oestradiol level was correlated with cervicovaginal epithelial function and glycogen and lactic acid secretion. Contraceptive initiation did not result in detectable ex vivo or in vitro increase of HIV-1 and HSV-2 susceptibility in cellular and tissue models. Contraceptive initiation during the first 3 months of use induced transient and variable changes in mucosal epithelial and immune markers, not leading to persistent alterations of the vaginal milieu or increased susceptibility to viral infections during the 3 months after contraception initiation. https://clinicaltrials.gov/study/NCT04814927?term=NCT04814927.&viewType=Card&rank=1, identifier NCT04814927.

PubMedRadiographics : a review publication of the Radiological Society of North America, Inc2026-10-15

Updated Terminology for Multidisciplinary Management of Intrauterine Devices: A Proposed Lexicon.

Jones Jill A JA, Boatright Christine M CM, Williams Vanessa L VL, Keller Jessica J JJ et al.

There are numerous terms used to describe variant locations of intrauterine devices (IUDs) in US reports, such as displaced, low lying, and malpositioned. These vague terms are frequently misinterpreted by providers and patients, which may lead to an incorrect inference of inadequate contraception. Current consensus guidelines from the American College of Obstetricians and Gynecologists (ACOG) indicate that the greatest risk of unintended pregnancy may be due to the unnecessary removal of a nonfundal IUD. Many providers now advocate leaving an IUD in place if it is located entirely above the internal os, as the device still provides effective contraception. The ACOG recommends counseling for patients, whether symptomatic or asymptomatic, before removal of the IUD. The authors outline a simple lexicon to describe the location of IUDs in US reports that includes terms understood by obstetrics and gynecology providers and that better align with current gynecologic literature. ©RSNA, 2026 Supplemental material is available for this article.

PubMedBJOG : an international journal of obstetrics and gynaecology2026-10-15

Efficacy and Safety of Lidocaine Compared to Other Agents for Intrauterine Device Insertion Pain: A Systematic Review and Meta-Analysis.

Pirrami Rachael G RG, Pandya Greeshma G, Islam Aminah A, Shaw Jalyn J et al.

Pain during intrauterine device (IUD) insertion remains a common barrier to use, with limited guidance on preferred pharmacological agents. Evaluate the efficacy and safety of lidocaine compared to other pharmacologic agents for reducing pain during IUD insertion. Electronic database searches were conducted in August 2025 and included randomized controlled trials (RCTs) published between January 1984 and August 2025. RCTs involving women or adolescents that evaluated the efficacy and safety of lidocaine versus other pharmacologic agents for reducing IUD insertion pain. Conducted in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) methodology. Risk of bias was assessed using the Cochrane Risk of Bias Tool for Randomized Trials (RoB-2) and meta-analysis was conducted on 5 of the 6 studies using Meta-Analysis version 4.0.2. Six studies (N = 658) compared lidocaine to non-steroidal anti-inflammatory drugs (NSAIDs) or misoprostol. Of these, two studies showed statistically significant pain reduction with lidocaine versus NSAIDs (study 1: 5.4 ± 2.8 vs. 7.3 ± 2.1, p < 0.001; study 2: 2.6 ± 0.9 vs. 4.1 ± 1.1, p < 0.001). The meta-analysis showed no statistically significant pain reduction with lidocaine overall. Lidocaine did not demonstrate a statistically significant reduction in pain. It remains unclear whether lidocaine, NSAIDs, and misoprostol are clinically comparable options. Secondary outcomes varied, and safety data were limited, highlighting the need for standardized endpoints. Further head-to-head trials are needed to guide optimal pain management for IUD insertion.

PubMedNeuropharmacology2026-10-15

N-acetylcysteine decreases toluene conditioned place preference and modulates corticostriatal activity in adolescent rats.

Carampel Ajina C AC, Asis Joannes Luke B JLB, Munar Johanna C JC, Gregorio Cynthia Grace C CGC et al.

Inhalant (toluene) use disorder (IUD) continues to be a public health problem especially among Filipino adolescents. Animal models of IUD have not yet explored neurobiological changes from chronic toluene exposure, or possible treatments for long-lasting toluene-induced deficits. In rats repeatedly exposed to 3000 ppm of toluene vapor over 12 days, we report that daily administration of N-acetylcysteine (NACys; 100 mg/kg i.p. or 0.9 g/l oral), but not melatonin (10 mg/kg i.p.), during 8 days of abstinence reduced toluene conditioned place preference in both male and female adolescent Sprague Dawley rats. Using immunofluorescence, we found that toluene-exposed rats showed decreased c-Fos densities in the dorsomedial striatum (DMS), dorsolateral striatum, and ventrolateral orbitofrontal cortex (vlOFC) after 8 days of abstinence. NACys partially rescued c-Fos expression in vlOFC. We found that c-Fos densities in both vlOFC and prelimbic cortex were significantly correlated with CPP values and with c-Fos densities in the DMS across treatment groups, suggesting that a history of toluene exposure may act by reducing cortical modulation of the dorsal striatum to promote long-lasting drug context seeking. Our findings suggest that NACys may be a promising treatment for IUD in adolescent males and females.

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about levonorgestrel